Cancer cells spreading to the liver—a deadly progression seen in uveal melanoma and colorectal cancer—may have found a molecular escape route that could become a new therapeutic target. The discovery reveals how metastatic cells manipulate cellular quality control systems to establish dangerous footholds in healthy liver tissue.
Researchers identified a three-protein signaling cascade where CDK6/4 kinases phosphorylate the tumor suppressor BAP1 at serine 369, effectively disabling its protective function. This phosphorylation prevents BAP1 from stabilizing VHL protein through deubiquitination, ultimately promoting cancer stem cell characteristics and epithelial-mesenchymal transition—both hallmarks of aggressive metastatic behavior. The team used mass spectrometry and proximity ligation assays to map these precise molecular interactions, then validated the pathway's role in liver colonization using mouse models.
This finding illuminates a critical vulnerability in cancer's metastatic machinery. BAP1 mutations are already known drivers in uveal melanoma, but this work demonstrates how even normal BAP1 can be functionally inactivated through post-translational modification. The VHL connection is particularly intriguing given its established role in oxygen sensing and angiogenesis regulation. From a therapeutic perspective, targeting CDK6/4 kinases—already FDA-approved for certain breast cancers—might prevent liver metastasis in high-risk patients. However, this represents early-stage mechanistic research requiring extensive clinical validation. The specificity of this pathway to liver metastasis, rather than other organs, suggests tissue-specific factors that warrant further investigation before translating to preventive interventions.